1-20 of 29
Wei Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, Mallorie H. Fiero, Sriram Subramaniam, Christy John, Wei Chen, Tiffany K. Ricks, Gang Niu, Anthony Fotenos, Min Wang, Kelly Chiang, William F. Pierce, Daniel L. Suzman, Shenghui Tang, Richard Pazdur, Laleh Amiri-Kordestani, Amna Ibrahim, Paul G. Kluetz
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (9): 1651–1657.
https://doi.org/10.1158/1078-0432.CCR-22-2875
Published: 01 May 2023
View article titled, FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Journal Articles

Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

Wei Chen, Hui Shi, Zhuojun Liu, Fan Yang, Jia Liu, Leqiang Zhang, Yajin Wu, Yuanshi Xia, Yuxuan Ou, Ruiting Li, Ting Zhang, Jiecheng Zhang, Xiaoyan Ke, Kai Hu, Jian Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1484–1495.
https://doi.org/10.1158/1078-0432.CCR-22-2924
Published: 14 April 2023
View article titled, Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
Open the PDF for Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

Ulka N. Vaishampayan, Archana Thakur, Wei Chen, Abhinav Deol, Meera Patel, Kimberlee Dobson, Brenda Dickow, Dana Schalk, Amy Schienschang, Sarah Whitaker, Amanda Polend, Joseph A. Fontana, Elisabeth I. Heath, Lawrence G. Lum
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 122–133.
https://doi.org/10.1158/1078-0432.CCR-22-1601
Published: 04 January 2023
View article titled, Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

IL15 and Anti–PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors

Wei Chen, Richard N. Bamford, Elijah F. Edmondson, Thomas A. Waldmann
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2082–2093.
https://doi.org/10.1158/1078-0432.CCR-21-0496
Published: 13 May 2022
View article titled, IL15 and Anti–PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors
Open the PDF for IL15 and Anti–PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors in another window
Includes: Supplementary data
Journal Articles

Correction: Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2

Jia-Xing Zhang, Zhen-Hua Chen, Yi Xu, Jie-Wei Chen, Hui-Wen Weng, Miao Yun, Zou-San Zheng, Cui Chen, Bing-Li Wu, En-Min Li, Jian-Hua Fu, Sheng Ye, Dan Xie
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4942.
https://doi.org/10.1158/1078-0432.CCR-21-2434
Published: 01 September 2021
View article titled, Correction: Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2
Open the PDF for Correction: Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2 in another window
Journal Articles

Correction: PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial–Mesenchymal Transition

Xin Chen, Ri-Xin Chen, Wen-Su Wei, Yong-Hong Li, Zi-Hao Feng, Lei Tan, Jie-Wei Chen, Gang-Jun Yuan, Si-Liang Chen, Sheng-Jie Guo, Kang-Hua Xiao, Zhuo-Wei Liu, Jun-Hang Luo, Fang-Jian Zhou, Dan Xie
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2664.
https://doi.org/10.1158/1078-0432.CCR-21-0936
Published: 01 May 2021
View article titled, Correction: PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial–Mesenchymal Transition
Open the PDF for Correction: PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial–Mesenchymal Transition in another window
Journal Articles

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Preeti Narayan, Tatiana M. Prowell, Jennifer J. Gao, Laura L. Fernandes, Emily Li, Xiling Jiang, Junshan Qiu, Jianghong Fan, Pengfei Song, Jingyu Yu, Xinyuan Zhang, Bellinda L. King-Kallimanis, Wei Chen, Tiffany K. Ricks, Yutao Gong, Xing Wang, Katherine Windsor, Steve Y. Rhieu, Gerlie Geiser, Anamitro Banerjee, Xiaohong Chen, Francisca Reyes Turcu, Deb K. Chatterjee, Anand Pathak, Jeffrey Seidman, Soma Ghosh, Reena Philip, Kirsten B. Goldberg, Paul G. Kluetz, Shenghui Tang, Laleh Amiri-Kordestani, Marc R. Theoret, Richard Pazdur, Julia A. Beaver
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (7): 1842–1849.
https://doi.org/10.1158/1078-0432.CCR-20-3652
Published: 01 April 2021
View article titled, FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
Open the PDF for FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer in another window
Journal Articles

FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer

Mirat Shah, Suparna Wedam, Joyce Cheng, Mallorie H. Fiero, Huiming Xia, Fang Li, Jianghong Fan, Xinyuan Zhang, Jingyu Yu, Pengfei Song, Wei Chen, Tiffany K. Ricks, Xiao Hong Chen, Kirsten B. Goldberg, Yutao Gong, William F. Pierce, Shenghui Tang, Marc R. Theoret, Richard Pazdur, Laleh Amiri-Kordestani, Julia A. Beaver
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1220–1226.
https://doi.org/10.1158/1078-0432.CCR-20-2701
Published: 01 March 2021
View article titled, FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer
Open the PDF for FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer in another window
Journal Articles

Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

Christina Wu, Terence M. Williams, Ryan Robb, Amy Webb, Lai Wei, Wei Chen, Sameh Mikhail, Kristen K. Ciombor, Dana B. Cardin, Cynthia Timmers, Somashekar G. Krishna, Mark Arnold, Alan Harzman, Sherif Abdel-Misih, Sameek Roychowdhury, Tanios Bekaii-Saab, Evan Wuthrick
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3117–3125.
https://doi.org/10.1158/1078-0432.CCR-19-4193
Published: 01 July 2020
View article titled, Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Open the PDF for Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A38: ATM inhibitor synergizes with glycolysis inhibition in ovarian cancer cells

Chi-Wei Chen, Erika S. Dahl, Kelly E. Leon, Raquel Buj, Katherine M. Aird
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A38.
https://doi.org/10.1158/1557-3265.OVCA19-A38
Published: 01 July 2020
View article titled, Abstract A38: ATM inhibitor synergizes with glycolysis inhibition in ovarian cancer cells
Journal Articles

ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer

Zhuqing Li, Wei Zhou, Yi Zhang, Wei Sun, Mingo M.H. Yung, Jing Sun, Jing Li, Chi-Wei Chen, Zongzhu Li, Yunxiao Meng, Jie Chai, Yuan Zhou, Stephanie S. Liu, Annie N.Y. Cheung, Hextan Y.S. Ngan, David W. Chan, Wei Zheng, Wenge Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (19): 5947–5960.
https://doi.org/10.1158/1078-0432.CCR-18-4145
Published: 01 October 2019
View article titled, ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer
Open the PDF for ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo

Brittany Woods, Wei Chen, Sophia Chiu, Christian Marinaccio, Chunling Fu, Lilly Gu, Marinka Bulic, Qiong Yang, Anouar Zouak, Shengxian Jia, Praveen Kumar Suraneni, Kailin Xu, Ross L. Levine, John D. Crispino, Qiang Jeremy Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (19): 5901–5912.
https://doi.org/10.1158/1078-0432.CCR-18-4089
Published: 01 October 2019
View article titled, Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation <em>In Vivo</em>
Open the PDF for Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis

Zhijun Zhou, Guanggai Xia, Zhen Xiang, Mingyang Liu, Zhewei Wei, Jie Yan, Wei Chen, Jintao Zhu, Niranjan Awasthi, Xiaotian Sun, Kar-Ming Fung, Yulong He, Min Li, Changhua Zhang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3317–3328.
https://doi.org/10.1158/1078-0432.CCR-18-3567
Published: 03 June 2019
View article titled, A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis
Open the PDF for A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis in another window
Includes: Supplementary data
Journal Articles

Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer

Joshua R. Heyza, Wen Lei, Donovan Watza, Hao Zhang, Wei Chen, Jessica B. Back, Ann G. Schwartz, Gerold Bepler, Steve M. Patrick
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2523–2536.
https://doi.org/10.1158/1078-0432.CCR-18-3094
Published: 15 April 2019
View article titled, Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer
Open the PDF for Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer in another window
Includes: Supplementary data
Journal Articles

PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial–Mesenchymal Transition

Xin Chen, Ri-Xin Chen, Wen-Su Wei, Yong-Hong Li, Zi-Hao Feng, Lei Tan, Jie-Wei Chen, Gang-Jun Yuan, Si-Liang Chen, Sheng-Jie Guo, Kang-Hua Xiao, Zhuo-Wei Liu, Jun-Hang Luo, Fang-Jian Zhou, Dan Xie
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (24): 6319–6330.
https://doi.org/10.1158/1078-0432.CCR-18-1270
Published: 13 December 2018
View article titled, PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial–Mesenchymal Transition
Open the PDF for PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial–Mesenchymal Transition in another window
Includes: Supplementary data
Journal Articles

Abstract PR05: SY-1425 (tamibarotene), a potent and selective RARα agonist, induces changes in the transcriptional regulatory circuit of AML cells leading to differentiation

Christopher M. Fiore, Michael R. McKeown, Emily Lee, Matthew L. Eaton, Darren Smith, Kathryn Austgen, Mei Wei Chen, Matthew Guenther, M. Ryan Corces, Ravindra Majeti, Eric Olson, Christian C. Fritz
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): PR05.
https://doi.org/10.1158/1557-3265.HEMMAL17-PR05
Published: 14 December 2017
View article titled, Abstract PR05: SY-1425 (tamibarotene), a potent and selective RARα agonist, induces changes in the transcriptional regulatory circuit of AML cells leading to differentiation
Journal Articles

Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2

Jia-Xing Zhang, Zhen-Hua Chen, Yi Xu, Jie-Wei Chen, Hui-Wen Weng, Miao Yun, Zou-San Zheng, Cui Chen, Bing-Li Wu, En-Min Li, Jian-Hua Fu, Sheng Ye, Dan Xie
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (1): 298–310.
https://doi.org/10.1158/1078-0432.CCR-16-0414
Published: 02 January 2017
View article titled, Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2
Open the PDF for Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2 in another window
Includes: Supplementary data
Journal Articles

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Amanda J. Walker, Suparna Wedam, Laleh Amiri-Kordestani, Erik Bloomquist, Shengui Tang, Rajeshwari Sridhara, Wei Chen, Todd R. Palmby, Jeanne Fourie Zirkelbach, Wentao Fu, Qi Liu, Amy Tilley, Geoffrey Kim, Paul G. Kluetz, Amy E. McKee, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (20): 4968–4972.
https://doi.org/10.1158/1078-0432.CCR-16-0493
Published: 13 October 2016
View article titled, FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Open the PDF for FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer in another window
Journal Articles

Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection

Ting-Jung Wu, Shih-Shin Chang, Chia-Wei Li, Yi-Hsin Hsu, Tse-Ching Chen, Wei-Chen Lee, Chau-Ting Yeh, Mien-Chie Hung
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1800–1812.
https://doi.org/10.1158/1078-0432.CCR-15-0780
Published: 31 March 2016
View article titled, Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection
Open the PDF for Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection in another window
Includes: Supplementary data
Journal Articles

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Julia A. Beaver, Laleh Amiri-Kordestani, Rosane Charlab, Wei Chen, Todd Palmby, Amy Tilley, Jeanne Fourie Zirkelbach, Jingyu Yu, Qi Liu, Liang Zhao, Joyce Crich, Xiao Hong Chen, Minerva Hughes, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Paul G. Kluetz, Geoffrey Kim, Amna Ibrahim, Richard Pazdur, Patricia Cortazar
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (21): 4760–4766.
https://doi.org/10.1158/1078-0432.CCR-15-1185
Published: 01 November 2015
View article titled, FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Open the PDF for FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer in another window